Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
|Articles|October 13, 2017
Lonza
Advertisement
Lonza is a leading partner to the pharmaceutical, healthcare, and life-science industries. For over 25 years, Lonza Custom Manufacturing has been helping emerging and large biotech and pharmaceutical companies improve and advance their products. Whether for clinical or commercial supply, Lonza’s complete development services, industry-leading manufacturing processes, and broad technology platforms enable products to reach their full potential.
Muenchensteinerstrasse 38, 4002 Basel, BS
info@lonza.com
tel. +41 61 316 81 11
AAPS Booth #1211
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement